Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM.CD40L vaccine in malignant melanoma
NCT00101166Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Oct 2004
- Primary completion
- Mar 2010
- Modality
- Gene Editing, Vaccines & Immunotherapeutics, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of granulocyte-macrophage colony-stimulating factor + CD40 ligand + autologous tumor cell vaccine in Malignant Melanoma (MM), sponsored by Moffitt Cancer Center. Started Oct 2004; status: completed.
02
Drugs
granulocyte-macrophage colony-stimulating factor + CD40 ligand + autologous tumor cell vaccine
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT00101166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00101166.